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Progression of diabetic nephropathy appears directly related
to renal tubulointerstitial injury, but the involved genes are
incompletely delineated. To identify such genes, DNA
microarray analysis was performed with RNA from renal
proximal tubules (RPTs) of streptozotocin-induced diabetic
Wistar rats, spontaneously diabetic BioBreeding rats, and rat
immortalized renal proximal tubular cells (IRPTCs) exposed to
high glucose (25 mM) medium for 2 weeks. Osteopontin
(OPN) mRNA expression was quantified by real
time-quantitative polymerase chain reaction (RT-qPCR) or
conventional reverse transcriptase-polymerase chain reaction
(RT-PCR). OPN mRNA expression was upregulated (5–70-fold
increase) in diabetic rat RPTs and in IRPTCs chronically
exposed to high glucose compared to control RPTs and
IRPTCs. High glucose, angiotensin II, phorbol 12-myristate
13-acetate and transforming growth factor-beta 1 (TGF-b1)
stimulated OPN mRNA expression in IRPTCs in a dose- and
time-dependent manner. This effect was inhibited by tiron,
taurine, diphenylene iodinium, losartan, perindopril, calphostin
C, or LY 379196 but not PD123319. IRPTCs overexpressing
dominant-negative protein kinase C-beta 1 (PKC-b1) cDNA or
antisense TGF-b1 cDNA prevented the high glucose effect
on OPN mRNA expression. We concluded that high
glucose-mediated increases in OPN gene expression in diabetic
rat RPTs and IRPTCs are mediated, at least in part, via reactive
oxygen species generation, intrarenal rennin–angiotensin
system activation, TGF-b1 expression, and PKC-b1 signaling.
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Renal proximal tubules (RPTs) play a role in tubulointer-
stitial fibrosis has been addressed recently.1–3 A number of
cytokine systems such as insulin-like growth factor-1,4
epidermal growth factor,5 endothelin-1,6 transforming
growth factor-beta 1 (TGF-b1),
7 and angiotensin II (Ang
II)8 have been implicated in tubulointerstitial injury.
Renin–angiotensin system (RAS) blockade and neutralizing
anti-TGF-b1 antibodies ameliorate renal hypertrophy and
suppress matrix protein mRNA expression in murine
RPTs,9,10 indicating the importance of these factors in the
progression of diabetic nephropathy.
Gene profiling studies concerning the development of
diabetic nephropathy11–16 have identified osteopontin
(OPN), as a candidate upregulated in experimental diabetic
glomerular disease. In the kidneys, OPN is normally
expressed in the descending thin limb of the loop of Henle
and collecting ducts of the medulla but is absent from renal
cortical tubules.17,18 OPN expression is, however, elevated in
established experimental models such as diabetic nephro-
pathy in the rat,19,20 models with unilateral ureteral
obstruction,21,22 and renal disease associated with cortical
tubulointerstitial fibrosis.23,24 Such observations, together
with the apparent role of OPN in inflammation and cell
reruitment, suggest that OPN may play a role in the
evolution of diabetic nephropathy.25
We performed DNA microarray profiling to identify genes
uniquely upregulated within diabetic rat RPTs. We observed
that OPN was upregulated both in diabetic rat RPTs and in
immortalized renal proximal tubular cells (IRPTCs) chroni-
cally exposed to high glucose. We then demonstrated that the
high glucose effect on OPN gene expression in IRPTCs is
mediated, at least in part, via reactive oxygen species (ROS)
generation, RAS activation, protein kinase C-beta 1 (PKC-b1)
signaling, and TGF-b1 gene expression.
RESULTS
Table 1 showed the physical data. Weight gain was
significantly lower after 2 weeks (day 14) of diabetes but
was improved with insulin treatment. Animals in both
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diabetic groups had elevated blood glucose and a higher ratio
of kidney weight/body weight as compared to non-diabetic
group. Normalization of blood glucose by insulin reversed
the ratio of kidney weight/body weight to non-diabetic levels.
Gene expression profiling in diabetic renal proximal tubular
cells
RAE230A expression chips analyzed the changes in mRNA
levels of 15 925 genes and expressed sequence tags (ESTs).
The percentage of these genes present in RPTs isolated from
non-diabetic BioBreeding (BB) rats, Wistar rats, and control
IRPTCs were 58.7, 57.8, and 28.9%, respectively. ESTs were
excluded in the analysis.
In RPTs isolated from diabetic BB rats, streptozotocin
(STZ)-induced diabetic Wistar rats, and high glucose-treated
IRPTCs, 144, 60, and 21 genes were upregulated, respectively
(Figure 1a), while 83, 37, and 13 genes were downregulated,
respectively (Figure 1b).
Only two genes, OPN and CCAAT enhancer binding
protein-delta (C/EBP-d), were commonly upregulated in
RPTs from diabetic BB rats, STZ-induced diabetic Wistar
rats, and high glucose-treated IRPTCs (Table 2). Tables 3 and
Table 1 | Physical parameters of the animals
Wistar rat BB rat
Control STZ STZ+Ins Non-diabetes Diabetes Diabetes+Ins
Body weight (g) – day 0 25774.1 24776.5 250711.8 222724.5 228741 219742.4
Body weight (g) – day 14 342718.9a 185715.6a,b 331715.0a,c 367725.8a 304744.1a,b 343728.2a,c
Blood glucose (mM) – day 0 7.970.7 7.870.7 8.076.2 6.970.3 9.175.5 6.870.2
Blood glucose (mM) – day 14 7.670.7 33.672.0a,b 6.275.9 6.670.5 31.576.6a,b 5.972.5
Kidney weight (g) 1.170.1 1.170.1 1.270.1 1.170.1 1.370.1 1.270.1
Ratio of body weight/kidney weight (% of control) 10075.8 192714.8d 11078.0e 10075.1 141710.4f 118710.5g
Ins=insulin; STZ, streptozotocin.
aPo0.001 when day 14 compared with day 0; n=8 for each group.
bPo0.001 when STZ (diabetes) compared with control (non-diabetes) ; n=8 for each group.
cPo0.001 when STZ+Ins (diabetes+Ins) compared with STZ (diabetes); n=8 for each group.
dPo0.01 when STZ compared with control; n=8 for each group.
ePo0.01 when STZ+Ins compared with STZ; n=8 for each group.
fPo0.05 when diabetes compared with non-diabetes; n=8 for each group.
gPo0.05 when diabetes+Ins compared with diabetes; n=8 for each group.
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Figure 1 | Common genes (a) upregulated and (b) downregulated
in diabetic RPTs from STZ-induced Wistar rats, spontaneously
diabetic BioBreeding (BB) rats, and high glucose-treated IRPTCs.
Data were compared with non-diabetic Wistar rats, BB rats, and
IRPTCs, respectively (n¼ 3 in each group).
Table 2 | Common genes upregulated in renal proximal
tubules (RPTs) of diabetic BioBreeding (BB) and Wistar rats,
and in rat immortalized renal proximal tubular cells (IRPTCs)
chronically exposed to high glucose for 2 weeks
Fold change
Genes (mRNA) BB Wistar IRPTCs
Mitochondrial 3-hydroxy-3-methylglutaryl-CoA
synthase mRNA
51.98 3.25
Insulin-like growth factor-binding protein 1
mRNA
12.13 3.25
Bile acid-coenzyme A dehydrogenase:
amino-acid n-acyltransferase mRNA
9.85 10.56
Organic anion transporter 5 mRNA 9.85 4.29
Cytochrome P450CMF1b mRNA 8.00 2.64
Kynurenine aminotransferase II mRNA 4.92 3.48
ATP-binding cassette, sub-family B (MDRTAP),
member 11 (Abcb11), mRNA
4.59 3.25
Deubiquitinating enzyme Ubp69 mRNA 4.29 5.66
Pregnancy-induced growth inhibitor
OKL38 mRNA
4.00 2.14
Rgc32 protein mRNA 4.00 2.00
Selenium-binding protein 2 mRNA 3.73 2.00
Basic helix–loop–helix domain-containing,
class B, 3 mRNA
3.48 2.46
17-b hydroxysteroid dehydrogenase
type 2 mRNA
3.48 2.46
Fibrinogen, an a polypeptide 3.25 2.46
Pyruvate dehydrogenase kinase,
isoenzyme 4 mRNA
3.25 2.00
Kruppel-like factor 15 (kidney) mRNA 2.83 2.64
Sulfotransferase SULT1A1 mRNA 2.83 2.64
Solute carrier 6, member 6 (taurine
transporter) mRNA
2.83 2.14
CCAAT enhancer-binding protein (CEBP)-d
mRNA
2.46 2.00 6.06
D site albumin promoter-binding protein 2.30 4.59
Osteopontin mRNA 2.30 4.59 3
Solute carrier family 2 A2 (glucose transporter,
type 2) mRNA
2.14 2.64
Glutamylcysteine-g synthetase light chain
mRNA
2.14 2.30
Nuclear receptor Rev-ErbA-b mRNA 2.00 2.30
Bold values indicate genes that are commonly regulated in all three groups of BB,
Wistar, and IRPTCs.
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4 identify the genes that most often increased or decreased in
RPTs from diabetic BB rats and STZ-induced diabetic Wistar
rats, respectively, with or without insulin treatment.
Validation of OPN mRNA expression in diabetic RPTs by real
time-quantitative polymerase chain reaction (RT-qPCR)
We used a specific RT-qPCR for rat OPN mRNA to validate
DNA microarray findings. Figure 2a, b, and c illustrate the
results of OPN mRNA expression in freshly isolated RPTs
from Wistar rats, BB rats, and IRPTCs, respectively. In Wistar
rats with STZ-induced diabetes, OPN mRNA expression was
increased approximately 70-fold (Po0.001) (n¼ 14) as
compared to the controls. This increment was reversed by
insulin treatment (Po0.001; n¼ 14). In BB rats, OPN mRNA
expression was elevated greater than fivefold in the diabetic
group as compared to the non-diabetic controls (Po0.001;
n¼ 10). Insulin treatment prevented the increase of OPN
mRNA in diabetic BB rats. The basal expression of OPN
mRNA in non-diabetic BB rats, however, was twofold higher
as compared to non-diabetic Wistar rats (Po0.01) (data not
shown). Prolonged exposure of IRPTCs to high glucose (i.e.,
25 mM) for 2 weeks also induced a fivefold increase
(Po0.001) in OPN mRNA expression compared to controls
incubated in normal glucose (5 mM) (n¼ 9). Insulin (107 M)
also reversed the high glucose effect on OPN mRNA
expression in IRPTCs (Po0.001; n¼ 9).
Effect of high glucose on OPN mRNA expression in IRPTCs
Quantification by conventional reverse transcription-poly-
merase chain reaction (RT-PCR) revealed that 25 mM
D-glucose stimulates OPN mRNA expression in IRPTCs in
a time-dependent manner (Figure 3a). A significant increase
of OPN mRNA expression (X2-fold) was observed after 24-h
incubation and rose progressively thereafter. In contrast,
25 mM D-mannitol had no significant effect, indicating that
upregulation of OPN gene expression is not due to increased
osmolarity (Figure 3b). Conventional RT-PCR for OPN
mRNA was subsequently used in all experiments.
Signaling mechanism of high glucose regulation of OPN
mRNA expression
To elucidate the underlying pathway of high glucose
regulation of OPN gene expression in IRPTCs, inhibitors
of several signaling pathways were tested. As illustrated in
Figure 4a, diphenylene iodinium (DPI) (1 106 M), tiron
(1 104 M), taurine (1 103 M), and Mn (III) tetrakis
(4-benzoic acid) porphyrin chloride (MnTBAP) (8 105 M)
blocked the effects of high glucose on OPN mRNA
expression. These results indicate that ROS generation might
mediate, at least in part, the high glucose effect on OPN
mRNA expression. Furthermore, high glucose effect on
OPN mRNA expression was inhibited in the presence of
losartan (1 106 M), perindopril (1 105 M), calphostin C
(1 107 M), and LY 379196 (1 107 M), but not in the
presence of PD123319 (an AT2R blocker) (1 105 M)
(Figure 4b). These results suggest that upregulation of OPN
gene expression by high glucose might be mediated, at least
in part, by intrarenal RAS activation and PKC signaling.
Effect of Ang II on OPN mRNA expression in IRPTCs
Figure 5a reveals that Ang II stimulated OPN mRNA
expression in IRPTCs with an optimal effect at 109 M. The
stimulatory effect of Ang II was inhibited in the presence of
losartan (1 106 M), calphostin C (1 107 M), LY 379196
(1 107 M), tiron (1 104 M), or DPI (1 106 M) but not
in the presence of PD123319 (1 105 M) or perindopril
(1 105 M) (Figure 5b). These data indicate that the Ang II
effect on OPN mRNA expression is mediated via AT1
receptor (AT1R) activation, ROS generation, and PKC
signaling but not AT2 receptor (AT2R).
PKC-b signaling and OPN mRNA expression in IRPTCs
To confirm the role of PKC signaling in OPN mRNA
expression, phorbol 12-myristate 13-acetate (PMA) was
added to the culture media. Figure 6a illustrates that PMA
stimulated OPN mRNA expression in a dose-dependent
manner (i.e., 1010–108 M). The addition of calphostin C
and LY 379196 (a PKC-b inhibitor) reversed the PMA action
on OPN mRNA expression (Figure 6b), demonstrating that
the PKC-b signaling pathway is important in regulating OPN
mRNA expression in IRPTCs.
Table 3 | Common genes downregulated in renal proximal
tubules (RPTs) of diabetic BioBreeding (BB) and Wistar rats
Fold change
Genes (mRNA) BB Wistar
Insulin-like growth factor-binding protein 5 19.70 3.25
Insulin-like growth factor-binding protein 5 3.48 2.14
Kidney androgen-regulated protein 13.93 6.06
Hemoglobin, a1 4.29 4.59
Hemoglobin, a1 3.48 3.48
Hemoglobin, a1 2.30 2.14
Calpain 6 4.29 2.30
Cyclooxygenase 2 4.00 2.14
Ly6-B antigen 4.00 2.00
Hydroxysteroid dehydrogenase, 11 b type 2 3.73 2.64
Stearoyl-coenzyme A desaturase 2 3.25 5.66
Hemoglobin, b 2.83 3.03
Hemoglobin, b 2.46 3.25
Protein associating with small stress protein PASS1 2.64 2.83
Thyroxine deiodinase, type I 2.64 2.64
Insulin-like growth factor I 2.64 2.64
SKR6 gene, a CB1 cannabinoid receptor 2.64 2.14
Solute carrier family 34 (sodium phosphate),
member 2
2.46 2.00
Fatty acid desaturase 1 2.14 2.14
Voltage-dependent calcium channel g subunit-like
protein
2.14 2.00
Prostaglandin D synthetase 2.00 2.30
Tissue-type transglutaminase 2.00 2.30
Cadherin EGF LAG seven-pas G-type receptor 2 2.00 2.14
Bold values indicate genes that are commonly downregulated in all two groups of
BB and Wistar.
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TGF-b1 and OPN mRNA expression in IRPTCs
Figure 7a and b reveal that TGF-b1 stimulated OPN mRNA
expression in IRPTCs in a dose- and time-dependent
manner, respectively. Calphostin C and LY 379196 inhibited
the stimulatory action of TGF-b1 on OPN mRNA expression
in IRPTCs (Figure 8a). In addition, TGF-b1 had no effect on
OPN mRNA expression in IRPTCs stably transfected with
dominant-negative PKC-b1 (Figure 8a). Furthermore,
IRPTCs stably transfected with sense TGF-b1 displayed
significantly higher basal OPN mRNA expression compared
to control cells (Po0.005), and high glucose further
enhanced OPN mRNA expression in these cells (Figure 8b).
In contrast, cells stably transfected with antisense TGF-b1
exhibited significantly lower OPN mRNA expression com-
pared to the controls (Po0.01) and did not respond to high
glucose stimulation (Figure 8b).
PKC-b1 mediates high glucose, TGF-b1, and Ang II effect on
OPN mRNA Expression
Figure 9a indicates that high glucose, TGF-b1, and Ang II
stimulated OPN mRNA expression but was abolished in
IRPTCs that were stably transfected with dominant-negative
(DN) PKC-b1. High glucose, TGF-b1,and Ang II also stimulated
PKC-b1 phosphorylation in IRPTCs (Figure 9b). Similarly, the
stimulatory effect of high glucose, TGF-b1, and Ang II on PKC-
b1 phosphorylation was also inhibited in DN PKC-b1 stable
clones. These data confirm that PKC-b1 may mediate, at least in
part, the stimulatory effect of high glucose, TGF-b1, and Ang II
action on OPN mRNA expression (Figure 10).
DISCUSSION
Among 227 and 97 differentially expressed transcripts in
RPTs from respective spontaneously diabetic BB rats and
Table 4 | Common genes regulated by insulin treatment
Fold change
BB Wistar
Genes (mRNA) Diabetesa Diabetes+Insulinb STZa STZ+Insulinb
Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 51.98 22.63 3.25 7.46
Insulin-like growth factor-binding protein 1 12.13 17.15 3.25 3.73
Bile acid-coenzyme A dehydrogenase: amino-acid n-acyltransferase 9.85 6.50 10.56 8.57
Organic anion transporter 5 9.85 6.06 4.29
Cytochrome P450CMF1b 8.00 2.83 2.64 2.46
Kynurenine aminotransferase II 4.92 3.03 3.48 2.64
ATP-binding cassette, sub-family B (MDRTAP), member 11 (Abcb11) 4.59 7.46 3.25 2.14
Deubiquitinating enzyme Ubp69 4.29 2.83 5.66 4.92
Pregnancy-induced growth inhibitor OKL38 4.00 2.14 2.14
Rgc32 protein 4.00 2.83 2.00
Selenium-binding protein 2 3.73 2.00 2.00
Basic helix–loop–helix domain-containing, class B, 3 3.48 2.83 2.46 4.92
17-b hydroxysteroid dehydrogenase type 2 3.48 3.25 2.46
Fibrinogen, an a polypeptide 3.25 3.73 2.46
Pyruvate dehydrogenase kinase, isoenzyme 4 3.25 3.73 2.00
Kruppel-like factor 15 (kidney) 2.83 2.83 2.64 2.30
Sulfotransferase SULT1A1 2.83 3.48 2.64 2.64
Solute carrier 6, member 6 (taurine transporter) 2.83 2.30 2.14 2.46
CCAAT enhancer-binding protein (CEBP)-d 2.46 3.73 2.00
D site albumin promoter-binding protein 2.30 4.59 3.03
Osteopontin 2.30 2.46 4.59 3.03
Solute carrier family 2 A2 (glucose transporter, type 2) 2.14 2.00 2.64 2.00
Insulin-like growth factor-binding protein 5 19.70 2.30 3.25 2.14
Kidney androgen-regulated protein 13.93 17.15 6.06 5.28
Hemoglobin, a1 4.29 2.46 4.59 2.00
Calpain 6 4.29 2.00 2.30
Hydroxysteroid dehydrogenase, 11 b type 2 3.73 2.64 2.46
Stearoyl-coenzyme A desaturase 2 3.25 4.59 5.66 3.48
Protein associating with small stress protein PASS1 2.64 4.00 2.83 2.83
Thyroxine deiodinase, type I 2.64 3.73 2.64 2.46
Insulin-like growth factor I 2.64 2.64 3.48
Fatty acid desaturase 1 2.14 3.03 2.14
Voltage-dependent calcium channel g subunit-like protein 2.14 2.30 2.00 2.30
Prostaglandin D synthetase 2.00 2.30 2.30 2.30
Tissue-type transglutaminase 2.00 2.14 2.30 2.14
Cadherin EGF LAG seven-pas G-type receptor 2 2.00 2.14 2.14 2.00
BB, bio breeding; STZ, streptozotocin.
Bold values indicate genes that are commonly up- or downregulated in two groups of BB and Wistar.
aDiabetic group compared with non-diabetic group.
bDiabetic with insulin treatment group compared with diabetic group.
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STZ-induced diabetic Wistar rats, only 43 were commonly
expressed in RPTs of both experimental diabetes models
(19% in BB rat RPTs, 44% in STZ-induced diabetic Wistar
rat RPTs).
OPN is one of two genes (CCAAT enhancer-binding
protein-d was the other) that is differentially upregulated in
diabetic rat RPTs and in IRPTCs chronically exposed to high
glucose. RT-qPCR confirmed this observation. OPN mRNA
expression levels in diabetic rat RPTs and in IRPTCs
chronically exposed to a high glucose milieu were 5–70-fold
higher than in control RPTs and IRPTCs. Insulin treatment
normalized OPN mRNA expression. These data are in agree-
ment with findings that OPN expression is enhanced in the
renal cortex and in mesangial cells of STZ-induced diabetic
rat kidneys20,26 and in human diabetic RPTCs.27,28 Surpris-
ingly, no apparent common gene (in comparison to diabetic
rat RPTs) appeared to be downregulated by insulin in
IRPTCs. While no explanation for this observation is evident,
one possible explanation based on our gene chip studies,
however, might be that a smaller percentage of genes is
expressed in IRPTC as compared to diabetic rat RPTs, that is,
28.9% in IRPTCs versus 58.7 and 57.8% in non-diabetic BB
rats and Wistar rats, respectively.
High levels of D-glucose upregulated OPN mRNA expres-
sion in a time- and dose-dependent manner. This stimulatory
effect of high glucose on OPN mRNA expression was
inhibited in the presence of DPI, tiron, taurine, MnTBAP,
losartan, perindopril, calphostin C, and LY 379196, suggesting
that the high glucose effect on OPN expression might be
mediated, at least in part, via ROS generation, RAS acti-
vation, and PKC-b signaling. At present, the exact molecular
linkage of high glucose and ROS on OPN expression is
incompletely delineated. One possibility may be that high
glucose evokes mitochondrial ROS generation with inhibi-
tion of glyceraldehyde-3-phosphate dehydrogenase activity
and flux of glucose to the tricarboxylic acid cycle but
stimulates the de novo synthesis of diacylglycerol (the polyol
pathway) and subsequently activates PKC-b.29,30 This possi-
bility is supported by our earlier work that high glucose
evokes ROS generation and activates the polyol/PKC pathway
with the outcome being angiotensinogen gene expression and
intrarenal RAS activation in IRPTCs.31,32
Losartan and perindopril but not PD123319 prevented the
stimulatory effect of high glucose on OPN mRNA expression.
Ang II stimulated OPN mRNA expression in IRPTCs, and its
effect was inhibited in the presence of losartan, calphostin C,
LY 379196, tiron, or DPI but not in the presence of
PD123319 and perindopril. These results further demonstrate
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Figure 2 | Typical analysis of OPN mRNA expression in (a) Wistar
rats, (b) BB rats, and (c) IRPTCs by real time-quantitative PCR (RT-
qPCR). After 2 weeks of diabetes, renal proximal tubules from Wistar
and BB rats and IRPTCs were collected and assayed for rat OPN mRNA
levels by RT-qPCR. The relative densities of OPN were normalized
with the b-actin control. OPN mRNA levels in (a) non-diabetic Wistar
rats, (b) BB rat, and (c) in IRPTCs incubated in normal glucose DMEM
were considered as 100%. Each point represents the mean7s.d. of 14
and 10 animals in (a) and (b), respectively, or (c) nine independent
experiments in IRPTCs. ***Pp0.001.
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Figure 3 | Effect of high glucose on rat OPN mRNA expression
in IRPTCs. (a) Cells were incubated in normal glucose DMEM with/
without 20 mM D-glucose for 24, 48, 72 h, 1 week, or 2 weeks. (b) Cells
were incubated in normal glucose DMEM with/without 20 mM
D-mannitol or 20 mM D-glucose for 48 h. Cells were collected and
assayed for rat OPN mRNA levels by conventional RT-PCR. The
relative densities of OPN were normalized with the b-actin control.
OPN mRNA levels in IRPTCs incubated in normal glucose DMEM were
considered as the control (100%). Each point represents the
mean7s.d. of four independent experiments performed in duplicate.
*Pp0.05; **Pp0.01; ***Pp0.001; NS, not significant.
Kidney International (2006) 69, 1005–1015 1009
T-J Hsieh et al.: Osteopontin expression in diabetic rat kidney o r i g i n a l a r t i c l e
that the stimulatory action of high glucose and Ang II
on OPN mRNA expression is mediated via AT1R activation
of nicotinamide adenine dinucleotide phosphate (reduced
form) oxidase evoking ROS generation and consequently
PKC-b1 activation in IRPTCs. These findings are similar to
others in that Ang II stimulated OPN expression in adult rat
ventricular myocytes and cardiac microvascular endothelial
cells, and these effects were blocked by DPI.33 Moreover, our
results are supported by the studies of Li et al.20 that long-
term treatment with ramipril attenuates OPN expression in
diabetic rat kidneys.
We tested PMA, a universal PKC activator to confirm PKC
signaling. Our results showed that PMA stimulated OPN
mRNA expression, and that its action was inhibited in the
presence of calphostin C and LY 379196. These data confirm
that PKC-b plays an important role in modulating
OPN expression in IRPTCs and support studies by others
disclosing that PKC signaling modulates OPN gene expres-
sion in different cell types34–36 and in tubular epithelial
cells of STZ-induced advanced experimental diabetic
nephropathy.37
TGF-b1 is a potent stimulus of OPN transcription and
protein expression in cultured rat renal epithelial cell line.38
Our data confirm that TGF-b1 upregulates OPN mRNA expre-
ssion, and its effect is inhibited in the presence of PKC-b
inhibitors as well as in IRPTCs stably transfected with DN
PKC-b1 cDNA. Furthermore, IRPTCs stably transfected with
sense TGF-b1 cDNA displayed a higher basal level of OPN
mRNA, and high glucose further enhanced OPN mRNA
expression. In contrast, stable transfection of IRPTCs with
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Figure 4 | Effects of antioxidants, PKC inhibitors and RAS blockers
on high glucose-induced OPN mRNA expression in IRPTCs.
(a) Cells were incubated for 48 h in normal glucose DMEM or 25 mM
D-glucose in the absence or presence of DPI (1 106 M), tiron
(1 104 M), taurine (1 103 M), or MnTBAP (80mM). (b) Cells were
incubated for 48 h in normal glucose DMEM or 25 mM D-glucose in the
absence or presence of losartan (1 106 M), PD123319 (1 105 M),
perindopril (1 105 M), calphostin C (1 107 M), or LY379196
(1 107 M). Cells were collected and assayed for rat OPN mRNA
levels by conventional RT-PCR. Each point represents the mean7s.d.
of four independent experiments performed in duplicate. *Pp0.05;
**Pp0.01; ***Pp0.001.
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absence or presence of antioxidants, PKC inhibitors, and RAS
blockers. (a) Cells were incubated for 24 h in the presence of
various concentrations of Ang II in medium containing 5 mM glucose.
(b) Cells were incubated for 24 h in normal glucose DMEM with/
without Ang II (109 M) in the absence or presence of losartan
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antisense TGF-b1 completely abolished the high glucose
effect on OPN mRNA expression. Stable transfection of
IRPTCs with DN PKC-b1 also attenuated the stimulatory
effect of high glucose, Ang II, and TGF-b1 on OPN mRNA
expression and PKC-b1 phosphorylation in IRPTCs. Our
report that PKC-b1 mediates the stimulatory effect of high
glucose, Ang II, and TGF-b1 on OPN gene expression in
RPTCs is novel. There is evidence that activation of PKC-e
and/or PKC-d can augment OPN mRNA expression in skin
cancer cells (JB6).34 Studies are ongoing to examine the effect
of other PKC isoform(s).
In summary, we have identified several novel transcripts
using DNA microarray profiling, subsequently confirmed
with RT-qPCR, that might be potential candidates to predict
the risk of developing diabetic nephropathy. Our data suggest
that ROS generation, intrarenal RAS and TGF-b1 gene
expression, and PKC-b1 activation may mediate, at least in
part, the high glucose effect on upregulation of OPN gene
expression in the diabetic kidney, ultimately leading to
tubulointerstitial fibrosis and end stage renal disease. We
would propose the following molecular pathway for high
glucose action on OPN gene expression in IRPTCs: First,
high glucose evokes ROS generation, and the resultant ROS
stimulate angiotensinogen gene expression and intrarenal
Ang II formation via different signaling pathways, including
PKC-b1. Subsequently, Ang II interacts with AT1R to activate
PKC-b1 signaling and also stimulate nicotinamide adenine
dinucleotide phosphate (reduced form) oxidase to evoke
ROS generation, which subsequently leads to further
enhancement of PKC-b1 activation. Ang II also stimulates
TGF-b1 gene expression and further augments PKC-b1
activation in IRPTCs. Finally, PKC-b1 stimulates OPN
expression in the diabetic kidney, potentially leading to
tubulointerstitial fibrosis and end stage renal disease.
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Figure 6 | PKC signaling on rat OPN mRNA expression in IRPTCs.
(a) Cells were incubated for 24 h in normal glucose DMEM in the
absence or presence of PMA at the dose of 1010–107 M. (b) Cells
were incubated for 24 h in normal glucose DMEM with/without PMA
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Figure 7 | Effect of TGF-b1 on rat OPN mRNA expression in IRPTCs.
(a) Cells were incubated for 24 h in normal glucose DMEM in the
absence or presence of active TGF-b1 at doses of 0.25–3 ng/ml.
(b) Cells were incubated in normal glucose DMEM with/without
TGF-b1 (2 ng/ml) for 6, 16, 24, or 48 h. Cells were collected and
assayed for rat OPN mRNA levels by conventional RT-PCR. Each point
represents the mean7s.d. of four independent experiments
performed in duplicate. **Pp0.01; ***Pp0.001; NS, not significant.
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MATERIALS AND METHODS
Chemicals and constructs
D-glucose, D-mannitol, human Ang II, PMA (a PKC activator),
calphostin C (a PKC inhibitor), DPI (a nicotinamide adenine
dinucleotide phosphate (reduced form) oxidase inhibitor), tiron (a
superoxide scavenger), taurine (an antioxidant), and PD123319 (an
AT2R blocker) were purchased from Sigma-Aldrich Canada Ltd
(Oakville, ON, Canada). Human TGF-b1 and MnTBAP a mimetic of
superoxide dismutase) were bought from R&D System (Cedarlane
Laboratories Ltd., Hornby, ON, Canada) and Calbiochem Inc. (La
Jolla, CA, USA), respectively. LY 379196 (a specific PKC-b isoform
inhibitor) was a gift from Elly Lilly (Indiana, IN, USA). Losartan
(a non-peptide AT1R blocker) and perindopril (an angiotensin-
converting enzyme inhibitor) were gifts from Dr Ronald D Smith
(Dupont Merck, Wilmington, DE, USA) and Dr Serge Carrie`re
(Servier Ame´rique, Laval, Quebec, Canada), respectively. Normal
glucose (5 mM) Dulbecco’s modified Eagle’s medium (DMEM,
catalogue no. 12320), 100 penicillin/streptomycin, and fetal
bovine serum were bought from InVitrogen, Inc. (Burlington,
ON, Canada). Oligonucleotides were synthesized by InVitrogen,
Inc. Restriction enzymes were acquired from either InVitrogen
Inc., Amersham-Pharmacia Biotech (Baie d’Urfe´, QC, Canada) or
5 mM
5 mM Calphostin C LY 379196 DN PKC-1
25 mM 5 mM 25 mM 5 mM 25 mM
TGF-1 sensepRC/RSV
5 25 5 25 5 25 (mM)
TGF-1 antisense
TGF-1 sense
+ TGF-1 (1 ng/ml)
TGF-1 (1 ng/ml) +
TGF-1
5 mM 5 mM Calphostin C LY 379196 DN PKC-1
pRC/RSV TGF-1 antisense
OPN
-Actin
200
100
0
0
200
400
600
R
at
io
 o
f o
st
eo
po
nt
in
/
-
a
ct
in
 m
R
N
A
(%
 of
 co
ntr
ol)
R
at
io
 o
f o
st
eo
po
nt
in
/
-
a
ct
in
 m
R
N
A
(%
 of
 co
ntr
ol)
OPN
-Actin
a
b
***
**
**
NS
*
**
**
****
Figure 8 | Effect of TGF-b1 on rat OPN mRNA expression in IRPTCs.
(a) Cells were incubated for 24 h in normal glucose DMEM with/
without TGF-b1 (1 ng/ml) in the absence or presence of calphostin C
(1 107 M), LY379196 (1 107 M) or stably transfected with
dominant-negative PKC-b1. (b) Cells stably transfected with pRC/RSV,
pRC/RSV-TGF-b1 cDNA in sense or antisense orientation were
incubated in normal glucose or 25 mM D-glucose for 48 h. Cells
were collected and assayed for rat OPN mRNA levels by conventional
RT-PCR. Each point represents the mean7s.d. of four independent
experiments performed in duplicate. *Pp0.05; **Pp0.01;
***Pp0.001.
5 mM 25 mM Ang IITGF-1 5 mM 25 mM Ang IITGF-1
5 mM 25 mM Ang IITGF-1
5 mM 25 mM
IRPTC DN PKC-1
Ang IITGF-1 5 mM 25 mM Ang IITGF-1
OPN
-Actin
200
300
100
0
R
at
io
 o
f o
st
eo
po
nt
in
/
-
a
ct
in
m
R
N
A 
(%
 of
 co
ntr
ol)
200
300
400
100
0R
at
io
 o
f p
ho
sp
o-
PK
C 
 1
/P
KC
 
1
pr
ot
ei
n 
(%
 of
 co
ntr
ol)
a
b
***
***
**
NS
NS
NS
NS
NS
NS
5 mM 25 mM
IRPTC DN PKC-1
IRPTC DN PKC-1
Ang IITGF-1
p-PKC-1
PKC-1
5 mM 25 mM Ang IITGF-1
***
**
**
5 mM 25 mM Ang IITGF-1
Figure 9 | Effect of high glucose, Ang II, and TGF-b1 on OPN
mRNA expression and PKC-b1 phosphorylation in IRPTCs stably
transfected with DN PKC-b1. (a) IRPTCs or IRPTCs stably transfected
with DN PKC-b1 were incubated for 24 h in 5 mM D-glucose plus 20 mM
D-mannitol in the presence of TGF-b1 (2 ng/ml) or Ang II (1 109 M)
or incubated in 25 mM D-glucose medium. Cells were collected and
assayed for rat OPN mRNA levels by conventional RT-PCR. (b) Cells
were harvested and assayed for PKC-b1 phosphorylation by Western
blotting with specific anti-phospho PKC-b1 antibodies. Each point
represents the mean7s.d. of four independent experiments
performed in duplicate. **Pp0.01; ***Pp0.001.
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La Roche Biochemicals (Laval, QC, Canada). Anti-PKC-b1 and anti-
phospho-PKC-b1 (T642) antibodies were purchased from Abcam
Ltd., Cambridge, UK.
The expression vector pcDNA 3.1 containing the dominant-
negative(DN) PKC-b1 cDNA with critical lysine in the ATP-binding
domains mutated to methionine was a gift from RV Farese
(University of South Florida, Tampa, FL, USA).39
We cloned a full-length rat TGF-b1 cDNA from IRPTCs using
conventional RT-PCR. Sense and antisense primers corresponding
to nucleotides Nþ 401 to Nþ 424 (50-GCC GCC TCC CCC ATG
CCG CCC TCG-30) and Nþ 1585 to Nþ 1565 (50-TCA GCT GCA
CTT GCA GGA GCG-30) of rat TGF-b1 cDNA
40 were used in
RT-PCR. The rat TGF-b1 cDNA with NotI restriction enzyme site
attached at both 50 and 30 termini was subsequently subcloned into
the NotI site of the expression vector pcDNA 3.1 (InVitrogen, Inc.)
in sense and antisense orientation.
Animals
Two animal models of insulin-dependent diabetes (type I) were
employed: spontaneously diabetic BB rats and STZ-induced diabetic
Wistar rats.41–45 Adult (60-day old) male BB rats were purchased
from Health Canada (Ottawa, ON, Canada), acclimatized for 2 days,
and blood sugar levels were measured every other day (Accu-Check
Compact, Roche Diagnostics, Laval, QC, Canada). BB rats with
blood glucose 425 mM were divided into two groups: untreated
diabetic (n¼ 4) and insulin-treated diabetic rats (n¼ 4, treated with
subcutaneous insulin implant, Linplant (Linshin, Scarborough, ON,
Canada) to maintain euglycemia). After 2 weeks of diabetes, the BB
rats were killed and kidneys were removed immediately for proximal
tubule isolation. Non-diabetic BB rats of the same age but without
diabetes served as controls (n¼ 4). This protocol was replicated
three times, total n¼ 12 per category.
All animals were allowed free access to rat chow and water. All
methods of animal care and killing were approved by the Animal
Care Committee of the Centre hospitalier de l’Universite´ de
Montre´al (CHUM).
Isolation of rat RPTs
At 2 weeks after diabetes was induced, the rats were anesthetized
and killed by decapitation at the same time point for each
group. Proximal tubule isolation was performed immediately
by Percoll gradient46 with slight modifications as described
previously.45
Cell culture
IRPTCs (Cell line #93-p-2-1 at passages 13–18) were employed.47
The culture conditions of IRPTCs have been described previously.48
IRPTCs were stably transfected with DNA using Lipofectamine
reagent (InVitrogen, Inc.) as previously described.48
For DNA microarray analysis, IRPTCs were grown for 2 weeks in
either 5 mM D-glucose plus 20 mM D-mannitol DMEM or 25 mM
D-glucose DMEM in the absence or presence of insulin (106 M)
mimicking the diabetic milieu. Then, total RNA was harvested for
DNA chip microarray analysis.
RNA extraction
Total RNA was extracted with Trizol reagent according to the
protocol of the supplier (InVitrogen, Inc.). Prior to DNA microarray
analysis, an additional cleanup step was used by employing an
RNeasy Mini Kit (QIAGEN Inc., Valencia, CA, USA).
DNA microarray analysis
Total RNAs from four individual rats in each group or four cell
culture dishes per treatment group were pooled and then reverse-
transcribed into cDNA, which, in turn, was used as a template for
the generation of biotin-labeled cRNA (Enzo kit, Affymetrix, Santa
Clara, CA, USA). The cRNA was fragmented and hybridized to
Affymetrix GeneChip RAE230A (Affymetrix) at the DNA Micro-
array Core Facility of the CHUM. The hybridized chips were stained
with streptavidin–phycoerythrin conjugate (InVitrogen, Inc.) and
then scanned by Agilent GeneArray 2500 Scanner (Affymetrix).
Quantitative analysis of hybridization patterns and intensities was
performed automatically by Affymetrix software, and the resulting
data were analyzed by Affymetrix Microarray Suite Version 5.0
software. Each GeneChip was evaluated by ‘single array analysis’ as
described by Affymetrix. The ‘fold change’ in gene expression
between the control and the diabetic groups was calculated by signal
log ratio and formulae were provided by Affymetrix.
RT-qPCR
Total RNA isolated from individual rat RPTs or IRPTCs was used for
RT-qPCR assay to quantify OPN and b-actin mRNA expression.
Briefly, 4 g of total RNA was used to synthesize first-strand cDNAs
by employing the Super-Script pre-amplification system (InVitro-
gen, Inc.). Then, the first-strand cDNA was used for RT-qPCR using
QuantiTectTM SYBR Green PCR Kit (Qiagen Inc., Valencia, CA,
USA) and Rotor-GeneTM 3000 (Montreal Biotech., Montreal, QC,
CA) according to the manufacturer’s protocol. PCR reactions in
triplicate underwent 44 cycles of 951C for 15 s, 601C for 15 s, and
721C for 30 s. After 44 cycles of amplification, PCRs were further
extended at 721C for 7 min. The parameter Ct (threshold cycle)
value was measured to determine starting copy number of target
genes using the standard curve. Lower Ct value indicates higher
amount of PCR products. The primers for OPN (AB001382.1) and
b-actin (NM_007393) are the following: sense OPN: 50-GCT CTC
AAG GTC ATC CCA GTT G-30 (N-556 to N-577 bp) and antisense
OPN: 50-TGT TTC CAC GCT TGG TTC ACT-30 (N-666 to
N-646 bp); sense b-actin: 50-CGT GCG TGA CAT CAA AGA GAA-30
(N-704 to N-724 bp) and antisense b-actin: GCT CGT TGC CAA
TAG TGA TGA (N-840 to N-820 bp).
Conventional RT-PCR
Conventional RT-PCR was used to amplify rat OPN and b-actin
cDNA fragments with the PCR core kit according to the supplier’s
instructions (InVitrogen, Inc.). After denaturation at 941C for
3 min, OPN or b-actin cDNA was amplified as follows: 941C for 20 s,
601C for 20 s, and 721C for 40 s. After 25 cycles of amplification,
PCRs were further extended at 721C for 5 min.
The sense and antisense rat OPN primers were 50-CTG GCA
GTG GTT TGC CTT TGC C-30 and 50-CGT CAG ATT CAT CCG
AGT TCA C-30, corresponding to the nucleotide sequences Nþ 86
to Nþ 100 and Nþ 389 to Nþ 410 of rat OPN cDNA,49
respectively. The sense and antisense rat b-actin primers were
50-ATG CCA TCC TGC GTC TGG ACC TGG C-30 and 50-AGC ATT
TGC GGT GCA CGA TGG AGG G-30, corresponding to the
nucleotide sequences Nþ 155 to Nþ 179 of exon 3, and nucleotide
sequences of Nþ 115 to Nþ 139 of exon 5 of the rat b-actin gene,50
respectively.
The digoxigenin method was used for detection with the
digoxigenin-labeled oligonucleotide 50-CAG ATG CTG TAG CCA
CTT GGC TGA AGC-30, corresponding to nucleotide Nþ 189 to
Nþ 215 of rat OPN cDNA.49 After OPN mRNA analysis, the same
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membrane was stripped and rehybridized with a b-actin oligo-
nucleotide probe (sequence: 50-TCC TGT GGC ATC CAT GAA ACT
ACA TTC-30, corresponding to nucleotides Nþ 9 to Nþ 35 of exon
4 of the rat b-actin gene.50 OPN mRNA levels were normalized by
corresponding b-actin mRNA levels.
Effect of high glucose, TGF-b1, and Ang II on PKC-b1
activation in IRPTCs
The effects of high glucose, TGF-b1, and Ang II on PKC-b1
activation in IRPTCs were assessed by Western blotting of phos-
phorylated PKC-b1. Briefly, IRPTCs and IRPTCs stable transfected
with DN PKC-b1 plasmid were synchronized overnight and then
incubated for 24 h in 5 mM D-glucose DMEM medium plus 20 mM
D-mannitol in the absence or presence of 2 ng/ml TGF-b1 or
10 109 M Ang II, or incubated in 25 mM D-glucose medium.
Western blotting was performed as described previously.51 The
membrane was initially blotted for phosphorylated PKC-b1 (T642)
antibody and then re-blotted for total PKC-b1 antibody.
Data and statistical analysis
Microarray data obtained from Affymetrix Microarray Suite Version
5.0 software were imported into Microsoft Excel 2000 for analysis.
All other calculations were performed by GraphPAD Prism Version
3.02 software. Three to four separate experiments were conducted
per protocol, and each treatment group was assayed in duplicate.
The data are expressed as mean7s.d. Statistical significance between
the groups was determined by one-way analysis of variance followed
by the Bonferroni test. A probability level of Po0.05 was considered
statistically significant.
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